Insider Ledger
ARWR insider buying and SEC filings, explained
Arrowhead Pharmaceuticals, Inc. · CIK 879407
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Sep 30
- Former names
- ARROWHEAD RESEARCH CORP; INTERACTIVE GROUP INC; INTERACTIVE INC
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$20.5M
Planned sales (10b5-1)
$16.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 18, 2026 | Sale | Michael S. Perry (Director) sold 11,600 shares at about $87.30 ($1.0M). Holdings down 9% to 111,459 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| Aug 18, 2026 | Sale | Adeoye Y. Olukotun (Director) sold 2,000 shares at $86.96 ($174K). Holdings down 6% to 31,600 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| May 12, 2026 | Planned (10b5-1) | Hongbo Lu (Director) sold 2,970 shares at $76.88 ($228K), marked as a 10b5-1 plan trade. Holdings down 5% to 52,012 shares. | SEC filing Filed May 14, 2026 |
| Apr 23, 2026 | Planned (10b5-1) | James C Hamilton (Chief Medical Officer) sold 10,000 shares at about $75.00 ($750K), marked as a 10b5-1 plan trade. Holdings down 4% to 226,958 shares. | SEC filing Filed Apr 24, 2026 |
| Apr 22, 2026 | Planned (10b5-1) | Daniel Joseph Apel (CFO) sold 13,095 shares at about $71.35 ($934K), marked as a 10b5-1 plan trade. Holdings down 7% to 162,905 shares. | SEC filing Filed Apr 24, 2026 |
| Mar 5, 2026 | Planned (10b5-1) | James C Hamilton (Chief Medical Officer) sold 10,000 shares at about $64.19 ($642K), marked as a 10b5-1 plan trade. Holdings down 4% to 236,958 shares. | SEC filing Filed Mar 9, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | James C Hamilton (Chief Medical Officer) sold 40,164 shares at about $63.11 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 19% to 171,958 shares. | SEC filing Filed Jan 5, 2026 |
| Jan 2, 2026 | Planned (10b5-1) | Christopher Richard Anzalone (CEO and Director) sold 13,187 shares at about $66.10 ($872K), marked as a 10b5-1 plan trade. Holdings down <1% to 3,792,739 shares. | SEC filing Filed Jan 5, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Patrick O'Brien (President / COO) sold 49,493 shares at about $63.11 ($3.1M), marked as a 10b5-1 plan trade. Holdings down 9% to 474,908 shares. | SEC filing Filed Jan 5, 2026 |
| Dec 29, 2025 | Planned (10b5-1) | Christopher Richard Anzalone (CEO and Director) sold 51,726 shares at about $69.13 ($3.6M), marked as a 10b5-1 plan trade. Holdings down 1% to 3,805,926 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 26, 2025 | Planned (10b5-1) | Mauro Ferrari (Director) sold 7,530 shares at $70.00 ($527K), marked as a 10b5-1 plan trade. Holdings down 10% to 69,053 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | Victoria Vakiener (Director) sold 10,040 shares at about $67.68 ($679K), marked as a 10b5-1 plan trade. Holdings down 22% to 35,723 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | William D. Waddill (Director) sold 8,367 shares at about $67.65 ($566K), marked as a 10b5-1 plan trade. Holdings down 13% to 56,563 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 19–22, 2025 | Planned (10b5-1) | Christopher Richard Anzalone (CEO and Director) sold 26,031 shares between Dec 19, 2025 and Dec 22, 2025 at about $68.04 ($1.8M), marked as a 10b5-1 plan trade. Holdings down 1% to 3,805,926 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 19, 2025 | Planned (10b5-1) | Adeoye Y. Olukotun (Director) sold 10,000 shares at about $67.66 ($677K), marked as a 10b5-1 plan trade. Holdings down 23% to 33,600 shares. | SEC filing Filed Dec 23, 2025 |
| Dec 17, 2025 | Sale | Christopher Richard Anzalone (CEO and Director) sold 85,000 shares at about $64.04 ($5.4M). Holdings down 2% to 3,831,957 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 19, 2025 |
| Dec 15–16, 2025 | Sale | Christopher Richard Anzalone (CEO and Director) sold 184,298 shares between Dec 15, 2025 and Dec 16, 2025 at about $67.00 ($12.3M). Holdings down 4% to 3,916,957 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 16, 2025 |
| Dec 5, 2025 | Sale | Michael S. Perry (Director) sold 16,250 shares at about $61.03 ($992K). Holdings down 12% to 115,240 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 9, 2025 |
| Nov 28, 2025 | Sale | Mauro Ferrari (Director) sold 8,750 shares at $56.39 ($493K). Holdings down 11% to 68,764 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 1, 2025 |
14 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ARWR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.